REATA PHARMACEUTICALS
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases. It offers antioxidant inflammation-modulating drugs, as well as drugs that correct protein misfolding. The company also develops drugs for the treatment of renal/cardiovascular and autoimmune diseases. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is based in Irving, Texas.
REATA PHARMACEUTICALS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2002-01-01
Address:
Irving, Texas, United States
Country:
United States
Website Url:
http://www.reatapharma.com
Total Employee:
51+
Status:
Active
Contact:
972-865-2219
Email Addresses:
[email protected]
Total Funding:
1.37 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Content Delivery Network Google Universal Analytics Microsoft Exchange Online Office 365 Mail
Similar Organizations
Aerial BioPharma
Aerial BioPharma is a biopharmaceutical company developing biologics and small molecules for central nervous system issues.
Anavex
Anavex is a biopharmaceutical company developing drugs for the treatment of cancer and neurological diseases.
Apexigen
Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics.
Aprecia Pharmaceuticals
Aprecia Pharmaceuticals develops precision drug delivery systems and products.
Ataxion
Ataxion is a discovery-stage biopharmaceutical company developing novel therapies for rare, debilitating, and underserved neurologic.
Atriva Therapeutics
Atriva is a biopharmaceutical company which aims to develop new antiviral therapies against different respiratory viral infections.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Cure Pharmaceutical
Cure Pharmaceutical is a specialty pharmaceutical and bioscience company, develops drug formulation and delivery technologies.
Emerald Health Pharmaceuticals
EHP is a biotech company developing biotechnology and cannabinoids science and technology to treat incurable diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Euthymics Bioscience
Euthymics Bioscience, a neuroscience-focused biopharmaceutical company, develops medicines for central nervous system disorders.
Genelux
Genelux, a clinical-stage biopharmaceutical company, develops diagnostic and therapeutic solutions for cancer and inflammatory diseases.
KeChow Pharma
KeChow Pharma, Inc. is a biopharmaceutical company focused on novel drug discovery.
Lumos Pharma
Lumos Pharma is a biopharmaceutical company that develops a novel treatment for the rare disease Creatine Transporter Deficiency.
MAIA Pharmaceuticals
MAIA Pharmaceuticals identifies, develops, manufactures and markets innovative and niche generic products.
NewBridge Pharmaceuticals
Newbridge Pharmaceuticals is a pharmaceutical and medical device company engaged in developing oncology and supportive care products.
PeriphaGen
PeriphaGen is a biopharmaceutical company whose corporate objective is the development of first in class neuronal gene delivery products.
Regeneron
Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
RegeneRx
RegeneRx is a biopharmaceutical company that designs, researches, and develops novel peptides targeted at diseases with unmet medical needs.
Relypsa
Relypsa is a biopharmaceutical company developing drugs for treating cardiovascular and renal diseases.
Reneo Pharmaceuticals
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.
Samsara Therapeutics
Samsara Therapeutics is a biopharmaceutical company that aims to discover therapeutics to treat rare genetic and neurodegenerative disease.
Selecta Biosciences
Selecta Biosciences is a clinical-stage biotechnology company with an unrelenting commitment to overcoming immunogenicity.
SpringWorks Therapeutics
SpringWorks Therapeutics is a biopharmaceutical company focused on developing medicines for patients with severe rare diseases and cancer.
Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company that develops novel therapies for neurodegenerative diseases.
TauRx Pharmaceuticals
TauRx Pharmaceuticals is a life sciences company developing drugs and diagnostics for neurodegenerative diseases.
Trevena
Trevena is a clinical stage biopharmaceutical company discovering and developing G-protein coupled receptors (GPCR) biased ligands.
Wren Therapeutics
Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Blackstone Life Sciences
Blackstone Life Sciences investment in Post-IPO Equity - Reata Pharmaceuticals
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Reata Pharmaceuticals
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Reata Pharmaceuticals
Novo Holdings
Novo Holdings investment in Venture Round - Reata Pharmaceuticals
CPMG
CPMG investment in Venture Round - Reata Pharmaceuticals
Novo Holdings
Novo Holdings investment in Series E - Reata Pharmaceuticals
CPMG
CPMG investment in Series E - Reata Pharmaceuticals
Startech Early Ventures
Startech Early Ventures investment in Series D - Reata Pharmaceuticals
Ojai Goliad
Ojai Goliad investment in Series D - Reata Pharmaceuticals
Cardinal Investment Co.
Cardinal Investment Co. investment in Series D - Reata Pharmaceuticals
Official Site Inspections
http://www.reatapharma.com Semrush global rank: 2.86 M Semrush visits lastest month: 5.66 K
- Host name: 198.180.131.91
- IP address: 198.180.131.91
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Reata Pharmaceuticals" on Search Engine
Reata Pharmaceuticals - Wikipedia
Reata Pharmaceuticals, Inc. is a pharmaceutical company based in Plano, Texas. Founded in 2002, it is primarily focused on investigating experimental oral antioxidative and anti-inflammatory drugs, [2] which dually activate the antioxidative transcription factor Nrf2 and inhibit the pro-inflammatory transcription factor NF-ฮบB .See details»
Reata Pharmaceuticals - Crunchbase Company Profile & Funding
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases. Acquired by. Biogen. Irving, Texas, United States. 251-500. Post-IPO Debt. Public. www.reatapharma.com. 7,197. Highlights. Stock Symbol NASDAQ:RETA. Total Funding Amount. Unlock for free. Contacts 296.See details»
Biogen Completes Acquisition of Reata Pharmaceuticals - Yahoo โฆ
CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) โ has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing...See details»
Biogen Completes Acquisition of Reata Pharmaceuticals
CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) โ has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases.See details»
Biogen to Acquire Reata Pharmaceuticals | Biogen
Jul 28, 2023 CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an โฆSee details»
Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio
July 28 (Reuters) - Biogen (BIIB.O) agreed to buy rare disease drugmaker Reata Pharmaceuticals (RETA.O) for nearly $6.5 billion, the first large acquisition under new CEO Christopher Viehbacher...See details»
Biogen to bulk up rare disease treatments with $7 billion Reata ...
Jul 28, 2023 By TOM MURPHY. Updated 6:23 AM PDT, July 28, 2023. Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments. The Alzheimerโs treatment developer said Friday it will pay $172.50 in cash for each share of Reata in a deal it expects to close by the end of this year.See details»
Reata Pharmaceuticals - Funding, Financials, Valuation & Investors
$2B. in funding over 16 rounds. Their latest funding was raised on May 10, 2023 from a Post-IPO Debt round. Reata Pharmaceuticals is registered under the ticker NASDAQ:RETA . Their stock opened with $11.00 in its May 26, 2016 IPO. Reata Pharmaceuticals is funded by 10 investors.See details»
Biogen to Acquire Reata Pharmaceuticals - Yahoo Finance
Jul 28, 2023 CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) today announced the companies have entered into a...See details»
U.S. FDA approves Reata's rare genetic disorder drug | Reuters
Mar 1, 2023 Feb 28 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc's (RETA.O) drug for the treatment of a rare genetic disorder that causes progressive...See details»
Biogen Completes Acquisition of Reata Pharmaceuticals
CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) โ has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing...See details»
Reata Announces FDA Accepted for Filing the NDA for
PLANO, Texas, April 26, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (โReata,โ the โCompany,โ or โweโ), a clinical-stage biopharmaceutical company, today announced that...See details»
Biogen to Acquire Reata Pharmaceuticals | Financial Post
Jul 28, 2023 CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) โ Biogen Inc. (Nasdaq: BIIB) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an โฆSee details»
Reata Pharmaceuticals Stockholders Approve Merger โฆ
Sep 21, 2023 Reata is a global, biopharmaceutical company committed to developing and commercializing novel therapeutics for patients with serious or life-threatening diseases with few or no approved...See details»
Biogen Completes Acquisition of Reata Pharmaceuticals
CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) โ Biogen Inc. (Nasdaq: BIIB) โ has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing...See details»
Skyclarys' Positive Reception Bolsters Reata's Future (RETA)
Mar 23, 2023 Reata Pharmaceuticals ( RETA) is a commercial-stage company specializing in the development of small-molecule therapeutics with unique mechanisms of action. Their focus is on treating severe...See details»
Biogen Completes Acquisition of Reata Pharmaceuticals
CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) โ has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing...See details»
Biogen's top dealmaker is keen on rare disease meds
Mar 5, 2024 Biotech. After tough rightsizing, Biogen looks to newer rare diseases to broaden lens. By Max Bayer Mar 5, 2024 10:20am. Biogen M&A Reata Pharmaceuticals business development. Top Biogen exec...See details»
STATEMENT: BIOGEN PROVIDES UPDATE ON THE ACQUISITION OF REATA ...
September 21, 2023. PDF Version. Biogen confirms that today Reata Pharmaceuticals announced in a special meeting the stockholders of the company voted to approve the companyโs previously announced acquisition by Biogen. For more information, read Reataโs Form 8-K disclosure. Stockholder Communications. E-mail Alerts. FAQs.See details»
Reata's stock soars 150% after FDA approves rare-disease drug โฆ
Mar 1, 2023 +0.41% The Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.โs treatment for Friedreichโs ataxia, a rare inherited disease that causes damage to the nervous system....See details»